NAVB Navidea Biopharmaceuticals, Inc. Stock Quote

NAVB [AMEX]

Index	-	P/E	-	EPS (ttm)	-0.40	Insider Own	27.80%	Shs Outstand	30.17M	Perf Week	5.81%
Market Cap	23.25M	Forward P/E	-	EPS next Y	-0.16	Insider Trans	0.00%	Shs Float	21.92M	Perf Month	-17.17%
Income	-11.70M	PEG	-	EPS next Q	-0.03	Inst Own	5.40%	Short Float	1.02%	Perf Quarter	-9.70%
Sales	0.50M	P/S	46.49	EPS this Y	16.10%	Inst Trans	-4.49%	Short Ratio	0.60	Perf Half Y	-41.84%
Book/sh	0.00	P/B	-	EPS next Y	46.70%	ROA	-119.90%	Target Price	5.00	Perf Year	-51.19%
Cash/sh	0.15	P/C	5.53	EPS next 5Y	-	ROE	-333.90%	52W Range	0.72 - 2.19	Perf YTD	-18.00%
Dividend	-	P/FCF	-	EPS past 5Y	15.90%	ROI	-	52W High	-62.56%	Beta	1.47
Dividend %	-	Quick Ratio	1.00	Sales past 5Y	-36.10%	Gross Margin	-	52W Low	13.89%	ATR	0.10
Employees	11	Current Ratio	1.00	Sales Q/Q	-50.00%	Oper. Margin	-	RSI (14)	44.93	Volatility	12.42% 11.57%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-7.80%	Profit Margin	-	Rel Volume	0.04	Prev Close	0.82
Shortable	Yes	LT Debt/Eq	-	Earnings	May 12 AMC	Payout	-	Avg Volume	374.59K	Price	0.82
Recom	2.00	SMA20	-11.84%	SMA50	-5.62%	SMA200	-32.81%	Volume	15,746	Change	0.00%

Nov-13-13

Reiterated

Aegis Capital

Hold

$3 → $2

Nov-07-13

Reiterated

Ladenburg Thalmann

Buy

$7.50 → $3

Jan-24-13

Initiated

Burrill Institutional Research

Mkt Outperform

Jan-22-13

Initiated

Aegis Capital

Hold

Sep-11-12

Reiterated

WBB Securities

Strong Buy

$9 → $7

Sep-11-12

Reiterated

Rodman & Renshaw

Mkt Outperform

$7 → $6

Sep-11-12

Reiterated

Ladenburg Thalmann

Buy

$6.25 → $7.50

May-12-22 07:30AM	Navidea Biopharmaceuticals Reports First Quarter 2022 Financial Results Business Wire -7.10%
May-05-22 07:30AM	Navidea Biopharmaceuticals to Host First Quarter 2022 Earnings Conference Call and Business Update Business Wire
Apr-20-22 06:58AM	Navidea Biopharmaceuticals Announces Positive Preliminary Results of Its Ongoing Phase 2B Study Comparing Tc99m Tilmanocept Imaging with Histopathology of Joints from Patients with Rheumatoid Arthritis Business Wire +10.10%
06:55AM	Navidea Biopharmaceuticals Announces Updated Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis for U.S. and EU Markets Business Wire
Apr-18-22 04:01PM	Navidea Biopharmaceuticals Announces the Regulatory Approval of Lymphoaim in India Business Wire
Apr-12-22 04:05PM	Navidea Biopharmaceuticals Announces Adoption of Plan Designed to Protect NOLs and Other Tax Assets, Closing of Bridge Loan Financing, and Business Update Q&A Series Business Wire
04:01PM	Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American Business Wire
Apr-07-22 07:30AM	Navidea Biopharmaceuticals Announces New Senior Regulatory Consultant and Return of Former Director of Regulatory Affairs Business Wire
Mar-23-22 03:44PM	CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results Business Wire
03:09PM	Again facing delisting, Dublin public company reports nearly $12M annual loss American City Business Journals
Mar-16-22 07:30AM	Navidea Biopharmaceuticals to Host Fourth Quarter 2021 Earnings Conference Call and Business Update Business Wire
Feb-07-22 07:30AM	Navidea Biopharmaceuticals Announces Research Agreement with the University of Pennsylvania Evaluating Tc99m Tilmanocept as a Prognostic Marker for Glioblastoma Business Wire +23.19%
Feb-03-22 04:01PM	Navidea Biopharmaceuticals Announces Settlement of Platinum Litigation; Receipt of Noncompliance Notice from NYSE American Business Wire
Dec-16-21 04:01PM	Navidea Biopharmaceuticals Announces Launch of Phase 3 Clinical Trial in Rheumatoid Arthritis Business Wire
07:58AM	Navidea Shares Gain After Terminating Stock Purchase Agreement Benzinga
Dec-15-21 04:02PM	Navidea Biopharmaceuticals Completes Full Enrollment in Phase 2b Normative Database Study to Support its Rheumatoid Arthritis Program Business Wire -6.45%
04:01PM	Navidea Biopharmaceuticals Terminates Stock Purchase Agreement Business Wire
Dec-13-21 07:30AM	Navidea Biopharmaceuticals Announces Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis Business Wire +8.47%
Dec-09-21 04:01PM	Navidea Biopharmaceuticals Announces Business Update Call and Changes to Board of Directors Composition Business Wire -6.40%
Nov-04-21 03:01PM	Will Navidea Biopharma (NAVB) Report Negative Q3 Earnings? What You Should Know Zacks
Nov-03-21 04:01PM	Navidea Biopharmaceuticals to Host Third Quarter 2021 Earnings Conference Call and Business Update Business Wire
Oct-26-21 05:22PM	Navidea Biopharmaceuticals Announces Resignation of Jed A. Latkin Business Wire
Oct-14-21 07:30AM	Navidea Biopharmaceuticals Appoints Thomas Forest Farb-Horch and Agnieszka Winkler to the Board of Directors Business Wire +5.42%
Sep-27-21 07:30AM	Navidea Biopharmaceuticals Appoints Michel Mikhail, Ph.D. as Chief Regulatory Officer Business Wire
Sep-20-21 09:07AM	4 Penny Stocks Insiders Are Buying Benzinga
Sep-17-21 07:30AM	Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition Business Wire
Aug-11-21 05:15PM	Navidea Biopharma (NAVB) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:01PM	Navidea Biopharmaceuticals Reports Second Quarter 2021 Financial Results Business Wire
Aug-04-21 07:30AM	Navidea Biopharmaceuticals to Host Second Quarter 2021 Earnings Conference Call and Business Update Business Wire
Jul-19-21 07:30AM	Navidea Biopharmaceuticals Announces First 110 Subjects Imaged in NAV3-35 Normative Database Phase 2b Study to Support Rheumatoid Arthritis Indications Business Wire
Jul-15-21 07:30AM	Navidea Biopharmaceuticals Announces End-of-Phase 2 Type B Meeting Request Granted by the FDA to Discuss Ongoing Clinical Program in Rheumatoid Arthritis Business Wire
Jun-24-21 07:00AM	Macrophage Therapeutics, Inc. Wins Delaware Case Against Michael Goldberg for Breach of Fiduciary Duty Business Wire
Jun-14-21 07:32PM	Here is What Hedge Funds Think About Navidea Biopharmaceuticals Inc (NAVB) Insider Monkey
May-19-21 07:30AM	Navidea Biopharmaceuticals Announces Issuance of U.S. Patent for Diagnosis and Treatment of Viral Infections Business Wire
May-11-21 04:01PM	Navidea Biopharmaceuticals Reports First Quarter 2021 Financial Results Business Wire
03:15PM	Navidea Biopharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
07:30AM	Navidea Biopharmaceuticals Announces NIH Grant Award to UC San Diego for Clinical Study Evaluating Tc99m Tilmanocept as a Kidney Imaging Agent Business Wire
May-05-21 08:00AM	Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition Business Wire
May-04-21 07:30AM	Navidea Biopharmaceuticals to Host First Quarter 2021 Earnings Conference Call and Corporate Update Business Wire
Apr-15-21 07:30AM	Navidea Biopharmaceuticals Announces Acceptance of Therapeutics Focused Abstract for Presentation at the Frontiers in Cancer Immunotherapy Symposium Business Wire
Mar-24-21 04:21PM	Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire -6.36%
02:45PM	Navidea Biopharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Mar-17-21 07:30AM	Navidea Biopharmaceuticals to Host Fourth Quarter 2020 Earnings Conference Call and Corporate Update Business Wire
Mar-02-21 04:01PM	Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference Business Wire
07:30AM	Navidea Biopharmaceuticals Announces $5 Million Private Placement with Existing Investor Business Wire
Feb-09-21 08:09AM	The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga
Feb-08-21 04:05PM	Navidea Biopharmaceuticals Announces Submission of Formal Type B Meeting Request with FDA and Launch of NAV3-32 Phase 2B Trial in Rheumatoid Arthritis Business Wire +5.64%
Jan-07-21 07:30AM	Navidea Biopharmaceuticals to Present at the 2021 ICR Conference On January 14, 2021 Business Wire
Dec-28-20 07:30AM	Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter Business Wire
Dec-08-20 09:51AM	New Strong Sell Stocks for December 8th Zacks -6.02%
Nov-26-20 06:34PM	Is Navidea Biopharmaceuticals Inc (NAVB) A Good Stock To Buy? Insider Monkey
Nov-12-20 04:02PM	Navidea Biopharmaceuticals Reports Third Quarter and Year-to-Date 2020 Financial Results Business Wire
04:01PM	Navidea Biopharmaceuticals Announces Positive Results Encompassing Additional Patients From Its Ongoing Phase 2B Study in Rheumatoid Arthritis Business Wire
03:15PM	Navidea Biopharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Nov-05-20 04:01PM	Navidea Biopharmaceuticals to Host Third Quarter 2020 Earnings Conference Call and Corporate Update Business Wire
Oct-29-20 12:35PM	Navidea Biopharma (NAVB) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
Oct-22-20 07:30AM	Navidea Biopharmaceuticals to Present at the Virtual Investor KOL Roundtable Business Wire
Oct-09-20 07:30AM	Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the American College of Rheumatology Annual Meeting Business Wire
Sep-28-20 07:30AM	Navidea Biopharmaceuticals to Ring Opening Bell at the New York Stock Exchange Business Wire +6.59%
Sep-08-20 04:05PM	Navidea Biopharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference Business Wire
Sep-02-20 04:05PM	Navidea Biopharmaceuticals Wins Dismissal of Platinum Loan Litigation Business Wire
Aug-31-20 05:00PM	(LD Micro) 360 Companies Set to Present this Week ACCESSWIRE +5.32%
Aug-24-20 04:05PM	Navidea Biopharmaceuticals to Present at The LD 500 Virtual Investor Conference Business Wire -9.06%
03:01PM	Breakeven On The Horizon For Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) Simply Wall St.
Aug-13-20 04:09PM	Navidea Biopharmaceuticals Reports Second Quarter and Year-to-Date 2020 Financial Results Business Wire +9.69%
Aug-10-20 09:08AM	Jubilant Radiopharma and Navidea Biopharmaceuticals Sign Binding Memorandum of Understanding for Commercialization Partnership Business Wire -27.62%
07:30AM	Navidea Biopharmaceuticals Signs Binding Framework for Commercialization Partnership with Jubilant Radiopharma Business Wire
Aug-06-20 04:15PM	Navidea Biopharmaceuticals to Host Second Quarter 2020 Earnings Conference Call and Corporate Update Business Wire
Aug-05-20 07:30AM	INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Navidea Biopharmaceuticals, Inc. for Potential Breach of Fiduciary Duty Claims ACCESSWIRE
Jun-25-20 03:50AM	Edited Transcript of NAVB earnings conference call or presentation 14-May-20 9:00pm GMT Thomson Reuters StreetEvents
Jun-17-20 09:43AM	Is the Options Market Predicting a Spike in Navidea Biopharmaceuticals (NAVB) Stock? Zacks
Jun-15-20 08:00AM	Navidea Biopharmaceuticals Announces Full Enrollment in its Ongoing Phase 2B Trial of Tc99m Tilmanocept in Rheumatoid Arthritis (RA) GlobeNewswire +8.36%
Jun-09-20 07:30AM	Navidea Biopharmaceuticals to Present at the Virtual Investor Fireside Chat Series GlobeNewswire
Jun-03-20 07:30AM	Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the European League Against Rheumatism (EULAR) Congress GlobeNewswire
May-26-20 10:11AM	Company News for May 26, 2020 Zacks
May-22-20 08:35AM	Navidea Biopharmaceuticals stock rockets toward 13-month high on heavy volume after update trial data MarketWatch +91.34%
07:10AM	The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray Benzinga
May-21-20 04:30PM	Navidea Biopharmaceuticals Announces Positive Results of Second Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis Business Wire
May-14-20 04:01PM	Navidea Biopharmaceuticals Reports First Quarter 2020 Financial Results Business Wire
May-11-20 07:30AM	Navidea Biopharmaceuticals Regains Commercialization and Distributions Rights in Europe for LYMPHOSEEK® Business Wire
May-07-20 07:00AM	Navidea Biopharmaceuticals to Host First Quarter 2020 Earnings Conference Call and Corporate Update Business Wire +7.67%
Apr-22-20 07:30AM	Navidea Biopharmaceuticals Provides Statement Regarding COVID-19 Pandemic Business Wire
Apr-21-20 08:52AM	What You Must Know About Navidea Biopharmaceuticals, Inc.'s (NYSEMKT:NAVB) Beta Value Simply Wall St.
Mar-31-20 07:30AM	Navidea Biopharmaceuticals Signs Letter of Intent with WorldCare Clinical to Partner on Navideas Rheumatoid Arthritis Clinical Imaging Workflow and Commercialization; Other Business Updates Business Wire
Mar-24-20 04:19PM	Edited Transcript of NAVB earnings conference call or presentation 11-Mar-20 9:00pm GMT Thomson Reuters StreetEvents
Mar-20-20 07:00AM	Navidea Biopharmaceuticals Announces Issuance of Patent Extension for Lymphoseek® Business Wire
Mar-11-20 04:05PM	Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results Business Wire
03:00PM	Navidea Biopharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Mar-04-20 08:00AM	Navidea Biopharmaceuticals to Host Fourth Quarter 2019 Earnings Conference Call and Corporate Update Business Wire +7.92%
Feb-21-20 08:42AM	Insider Buying: John Scott Just Spent US$2.0m On Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) Shares Simply Wall St.
Feb-14-20 11:56AM	Navidea Biopharmaceuticals Regains Compliance with NYSE American Continued Listing Standards Business Wire +20.41%
07:28AM	Navidea Biopharmaceuticals Announces $4.2 Million Sale of Ohio Court Judgment and $3.4 Million Equity Raise Representing $7.6 Million in Additional Funding Business Wire
Feb-12-20 09:20AM	Investors Who Bought Navidea Biopharmaceuticals (NYSEMKT:NAVB) Shares Five Years Ago Are Now Down 97% Simply Wall St.
Dec-30-19 05:19PM	Navidea Biopharmaceuticals Obtains Partial Dismissal of Claims in New York Business Wire +6.89%
Dec-14-19 09:41AM	The of Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB), John Scott, Just Bought 11% More Shares Simply Wall St.
Dec-06-19 06:23PM	Navidea Biopharmaceuticals Announces $1.9 Million Private Placement Business Wire +10.32%
Dec-05-19 03:45PM	Navidea Biopharmaceuticals to Present at the 12th Annual LD Micro Main Event Business Wire
Dec-02-19 02:08PM	Navidea Biopharmaceuticals Wins Summary Judgment in Ohio Business Wire +7.19%
Nov-19-19 10:41PM	Edited Transcript of NAVB earnings conference call or presentation 7-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-14-19 08:30AM	Navidea Biopharmaceuticals to Present at the PCG Spotlight Series Conference Business Wire

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. Further, the company offers NAV4694 and NAV5001, a neuro-tracer product candidates. In addition, it is developing diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Witter Malcolm G	Director	Sep 17	Buy	1.60	20,000	31,952	98,257	Sep 17 04:41 PM
Witter Malcolm G	Director	Jul 26	Buy	1.70	15,000	25,470	78,257	Jul 26 04:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience